Gastric inhibitory polypeptide

Summary

Gastric inhibitory polypeptide (GIP), also called glucose‑dependent insulinotropic polypeptide, is a gut‑derived incretin hormone released after nutrient ingestion. It binds the GIP receptor (GIPR) on pancreatic β‑cells and other tissues to modulate insulin secretion, β‑cell growth, fat storage, bone formation and brain function. While GIP alone is not an approved drug, it is a key component of newer dual‑ and triple‑agonist therapies under investigation for obesity and type‑2 diabetes.

Mechanism of Action

GIP circulates to target cells expressing the GIPR, a G‑protein‑coupled receptor that activates adenylate cyclase, raising intracellular cAMP. The rise in cAMP potentiates glucose‑dependent insulin release from β‑cells, promotes β‑cell proliferation and reduces apoptosis. In adipose tissue GIP stimulates lipogenesis, in bone it enhances formation, and in the brain it participates in appetite and memory pathways. These actions are distinct from, but often complementary to, those of GLP‑1.

What the Research Shows

Human studies show that after diet‑induced weight loss, circulating GIP rises and remains elevated for at least a year, coinciding with increased appetite and potential weight‑regain (Sumithran et al., 2011). Reviews of incretin physiology describe GIP’s insulinotropic, anabolic, and neurocognitive roles (Seino et al., 2010). Clinical trials of GIP‑containing agonists report metabolic benefits: the triple agonist retatrutide (GLP‑1/GIP/glucagon) produced ~14% weight loss, lowered fasting glucose and HbA1c, with adverse events comparable to placebo (Abdrabou et al., 2025). The dual GIP/GLP‑1 agonist tirzepatide, approved for type‑2 diabetes, achieved up to 12.9 kg weight loss and 3 % HbA1c reduction, with a safety profile similar to GLP‑1 analogues (Sinha et al., 2023). These data suggest that GIP contributes to the efficacy of multi‑agonist regimens, though isolated GIP effects remain less clear.

Reported Benefits

Evidence from multi‑agonist trials indicates that GIP‑containing agents can improve body weight, fasting glucose, HbA1c, blood pressure and lipid parameters in obese or diabetic adults. Pre‑clinical and clinical observations also suggest that GIP may support β‑cell mass and bone health, and influence central appetite pathways, offering potential advantages beyond glucose control when combined with GLP‑1 or glucagon activity.

Limitations of the Evidence

The insulinotropic effect of GIP is markedly blunted in people with type‑2 diabetes, limiting its standalone therapeutic value. Most clinical data involve GIP as part of dual or triple agonists, so the specific contribution of GIP remains uncertain. Long‑term safety and durability of GIP‑centric therapies are still under investigation, and no GIP‑only drug has received regulatory approval.

Safety Considerations

In the retatrutide trials, the overall rate of adverse events was similar to placebo (relative risk 1.11, non‑significant). Tirzepatide, which includes GIP activity, was reported as well tolerated with a side‑effect profile comparable to existing GLP‑1 analogues, primarily gastrointestinal symptoms. Direct safety data for isolated GIP administration are lacking, and caution is advised until dedicated studies clarify its risk profile.

How It Is Administered

Research formulations of GIP or GIP‑containing agonists are delivered by intravenous or subcutaneous injection. In clinical trials, subcutaneous administration is most common, often once weekly for long‑acting peptide analogues. Dosing regimens vary by compound and are defined in study protocols rather than standard therapeutic guidelines.

Routes of Administration

Goals & Uses

• Weight managementBody CompositionLow
• Type 2 diabetes managementEndocrine / MetabolicModerate
• Bone anabolismMusculoskeletalModerate
• Improve glycemic controlMetabolicModerate
• Obesity / weight managementMetabolicModerate
• Research tool for incretin biologyResearchHigh
• Augment insulin secretionMetabolicHigh

Contraindications

• Severe hypersensitivity to peptide preparationAllergyHigh
• Known hypersensitivity to GIP or excipientsAllergicHigh
• Insulinoma or conditions predisposing to hypoglycemiaEndocrineModerate

Adverse Effects

• Hypoglycemia (when combined with insulin or sulfonylureas)MetabolicUncommon
• HypoglycemiaMetabolicUncommonAbnormally low blood glucose
• Injection site reactionsLocalCommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Increased fat depositionMetabolicUnknown

Drug Interactions

• InsulinModerateMay increase risk of low blood sugar
• SulfonylureasModerateMay increase risk of low blood sugar
• DPP-4 inhibitors (e.g., sitagliptin)Low

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric populationsAgeRelative
• Pediatrics (<18 years)AgeRelative

Regulatory Status

• European UnionInvestigationalSame as US.
• United StatesInvestigationalNative GIP not approved; GIP‑based analogs in Phase II/III trials.
• United KingdomUnapprovedNot approved by MHRA as a standalone therapeutic agent.

The native peptide is not an approved drug; several GIP‑based analogs are in clinical development, while dual GIP/GLP‑1 agonists (e.g., tirzepatide) have received regulatory approval for type 2 diabetes.

Evidence & Sources

• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
  Journal ArticleModerateAbdrabou Abouelmagd A, et al.2025-01-01T00:00:00.000000Z
• Long-term persistence of hormonal adaptations to weight loss
  Journal ArticleModerateSumithran P, et al.2011-01-01T00:00:00.000000Z
• Autophagy in the physiological endometrium and cancer
  Journal ArticleModerateDevis-Jauregui L, et al.2021-01-01T00:00:00.000000Z
• Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
  Journal ArticleModerateSinha R, et al.2023-01-01T00:00:00.000000Z
• Incretin hormones and type 2 diabetes
  Journal ArticleModerateNauck MA, Müller TD2023-01-01T00:00:00.000000Z
• GIP and GLP-1, the two incretin hormones: Similarities and differences
  Journal ArticleModerateSeino Y, Fukushima M, Yabe D2010-01-01T00:00:00.000000Z

Frequently Asked Questions